Royalty Report: Drugs, Therapeutic, Pharmaceuticals – Collection: 6647

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Pharmaceuticals
  • Pain
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6647

License Grant
The Company entered into a License Agreement granting exclusive rights to develop and commercialize DM-1796 for pain indications in the United States, Canada and Mexico.
License Property
DM-1796 is for post-herpetic neuralgia.
Field of Use
In March 2010, the Licensee submitted a New Drug Application for DM-1796 to the U.S. Food and Drug Administration for the management of post-herpetic neuralgia.

IPSCIO Record ID: 3948

License Grant
Licensor grants to Dutch Licensee under the Licensor's Technology (i) an exclusive license to develop, have developed, make, have made, use, market, have marketed, promote, have promoted, commercialize, have commercialized, exploit, import, export, sell, have sold and offer to sell the Product and (ii) a nonexclusive license to develop, have developed, make, have made, import and export the Product.

The Licensor will remain responsible for completion of the ongoing Phase 3 clinical trial for DM-1796 for the treatment of pain associated with post-herpetic neuralgia.  The Licensee will be responsible for the NDA filing and has the option to develop DM-1796 in further pain indications other than post-herpetic neuralgia.

License Property
Licensor has used its proprietary AcuForm™ gastric retentive technology to develop an oral dosage form of gabapentin known as Gabapentin GR®, and is conducting Phase III clinical development of Gabapentin GR®.

“Product” means the product known as Gabapentin GR® in the formulation and at the dosage being studied in Depomed Protocol 81-0062, “A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients with Postherpetic Neuralgia,” dated the 25th day of January, 2008, and any alternative strengths of such dosage form, or line extensions of such product for use within the Field.

Extending the duration of drug release within the stomach during the fed mode

6,340,475

1/22/2002

U.S.

Extending the duration of drug release within the stomach during the fed mode

6,635,280

10/21/2003

U.S.

Optimal polymer mixtures for gastric retentive tablets

6,723,340

4/20/2004

U.S.

Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage form

6,488,962

12/3/2002

U.S.

Methods of Treatment using a Gastric Retained Gabapentin Dosage

7,438,927

10/21/2008

U.S.

Field of Use
Field means the treatment or amelioration of pain, including without limitation treatment of post-herpetic neuralgia (“PHN”), pain associated with diabetic neuropathy (“DPN”), Phantom Pain and fibromyalgia.

IPSCIO Record ID: 6808

License Grant
The Licensee entered into a License Agreement with the Licensor, for the sole and exclusive right to develop, use, market, promote and sell Lidoderm in the United States. In addition, The Licensee pays the Licensor non-refundable royalties based on net sales of Lidoderm. Royalties are recorded as a reduction to net sales due to the nature of the License Agreement and the characteristics of the License involvement by the Licensor in Lidoderm.
License Property
Lidoderm® (lidocaine patch 5%) is an FDA approved lidocaine -based patch, available by prescription, that can be applied to the skin for pain relief from postherpetic neuralgia, commonly called after-shingles pain.
Field of Use
The rights granted apply to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.